Alamar Biosciences Expands Neurodegenerative Disease Partnership
FREMONT, California, August 10, 2026 Alamar Biosciences, Inc. announced an expansion of its strategic partnership with the Alzheimer’s Disease...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FREMONT, California, August 10, 2026 Alamar Biosciences, Inc. announced an expansion of its strategic partnership with the Alzheimer’s Disease...
FREMONT, Calif., July 28, 2026 Alamar Biosciences, Inc. has announced the commercial launch of the NULISAseq™ Immune 340 Panel,...
OSAKA, Japan; CAMBRIDGE, Massachusetts; JAKARTA, Indonesia — July 13, 2026 Takeda has entered into a landmark collaboration with the...
FREMONT, California, July 13, 2026 Alamar Biosciences has partnered with leading U.S. research universities to launch a national-scale proteomics...
FREMONT, California, USA, June 2, 2026 Alamar Biosciences has unveiled its NULISA™ Dried Blood Spot (DBS) Extraction Kit, a...
FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ — Alamar Biosciences, a leader in precision proteomics, today announced the launch of...
